摘要
目的:观察重组人白介素-11(I)(百杰依)对恶性肿瘤患者因化疗所致血小板减少的疗效及不良反应。方法:化疗后发生Ⅲ级以上血小板减少(PLT≤50×109/L)即开始给予百杰依25μg/(kg·d)皮下注射,观察外周血小板变化,血小板升至100×109/L以上或绝对值升高50×109/L以及使用10支百杰依时停药。结果:患者采用百杰依治疗前后对比数据显示,化疗前血小板计数平均值为(136.0±36.84)×109/L,化疗后血小板最低值为(25.58±12.90)×109/L,血小板<50×109/L持续天数为(5.42±3.47)天,百杰依治疗结束时血小板计数平均值为(106.91±55.44)×109/L,平均用药天数(6.91±2.5)天。主要不良反应为头晕、注射部位疼痛、水肿。结论:重组人白介素-11(I)(百杰依)有升高化疗后血小板减少的作用,疗效显著,毒副反应可耐受。
Objective：To observe the efficacy and side effects of recombinant human interleukin-11 in the treatment of thrombocytopenia caused by chemotherapy in patients with malignancies.Methods：Platelets after chemotherapy less than 50 × 10^9/ L were injected subcutaneously with recombinant human interleukin-11 25μg /（ kg·d）,observe changes in peripheral platelet until the counts of platelets up to 100 × 10^9/ L.Results：The average of platelets before chemotherapy was（136.0 ± 36.84） × 10^9/ L,the minimum platelets after chemotherapy was（25.58 ± 12.9） ×10^9/ L）,the duration of the platelets 50 × 10^9/ L was（5.42 ± 3.47） days.The average of platelets at the end of treatment was（106.91 ± 55.44） × 10^9/ L.The average days use rh IL-11 was（ 6.91 ± 2.5） days.The main side effects were diarrhea,pain at the injection site,edema.Conclusion：Recombinant human interleukin-11（ rh IL-11）can elevate blood platelet count caused by chemotherapy,adverse reactions can be tolerated.
出处
《现代肿瘤医学》
CAS
2015年第6期850-852,共3页
Journal of Modern Oncology
